NASDAQ:IMCR Immunocore Q3 2024 Earnings Report $32.56 +0.39 (+1.20%) As of 10:09 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immunocore EPS ResultsActual EPS$0.17Consensus EPS -$0.33Beat/MissBeat by +$0.50One Year Ago EPS-$0.59Immunocore Revenue ResultsActual Revenue$80.25 millionExpected Revenue$78.94 millionBeat/MissBeat by +$1.31 millionYoY Revenue Growth+23.70%Immunocore Announcement DetailsQuarterQ3 2024Date11/6/2024TimeBefore Market OpensConference Call DateWednesday, November 6, 2024Conference Call Time7:00AM ETUpcoming EarningsImmunocore's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immunocore Earnings HeadlinesImmunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 22 at 4:29 AM | americanbankingnews.comImmunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.com“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown, founder of Brownstone Research, calls it M.A.G.I. Venture capitalist Jason Calacanis, who turned $100,000 into $100 million from Uber's IPO, previewed the technology privately and called it the best selling product he has ever seen.September 22 at 1:00 AM | Brownstone Research (Ad)Immunocore Completes Enrollment in Study of Potential Advanced Melanoma TreatmentSeptember 14, 2026 | finance.yahoo.comImmunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanomaSeptember 14, 2026 | globenewswire.comImmunocore to present at upcoming investor conferencesSeptember 1, 2026 | globenewswire.comSee More Immunocore Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email. Email Address About ImmunocoreImmunocore (NASDAQ:IMCR) Holdings plc is a biotechnology company that develops T-cell receptor (TCR) therapies designed to direct the immune system against cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-related peptides presented on the surface of cells and recruit T cells to destroy targeted cells. The company’s lead product is KIMMTRAK (tebentafusp-tebn), an ImmTAC therapy approved in the United States, European Union and other markets for the treatment of unresectable or metastatic uveal melanoma in certain patients. KIMMTRAK is designed to target gp100, a protein expressed by melanoma cells, and activate T cells against the tumor. Immunocore is headquartered in Abingdon, United Kingdom, and serves international markets through its commercial and development activities. In addition to uveal melanoma, the company is advancing a pipeline of ImmTAC candidates being studied in other cancers, as well as exploring potential applications in infectious and autoimmune diseases. Bahija Jallal has served as Immunocore’s chief executive officer since 2019. The company was founded in the United Kingdom and became publicly traded on the Nasdaq Stock Market in 2021 under the symbol IMCR.View Immunocore ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep Winning Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
